Shenzhen Crystalo Biopharma Technology Co. Ltd. has divulged short transient receptor potential channel 5 (TRPC5) antagonists reported to be useful for the treatment of anxiety, depression, post-traumatic stress, diabetic nephropathy and focal segmental glomerulosclerosis.
Shanghai Institute of Organic Chemistry has prepared and tested microtubule destabilizers (tubulin polymerization inhibitors) reported to be useful for the treatment of cancer, traumatic brain injury, multiple sclerosis, and Alzheimer’s, Huntington's and Parkinson's disease.
Abata Therapeutics Inc. announced it has received an equity investment from Bristol Myers Squibb to support the development of its Treg cell therapy products. Their investment supports Abata's continued advancement into the clinic, with trial initiation imminent for ABA-101 in progressive multiple sclerosis (MS). Abata obtained FDA clearance for a first-in-human study of ABA-101 in patients with MS in July.
Spinal cord injury (SCI) is characterized by extensive demyelination and inflammatory responses. The clearance of microglial lipid droplets contributes to neural recovery and remyelination. Putting the focus on investigating microRNAs that regulate lipid homeostasis after SCI was the objective of a recently published study.
Otsuka Precision Health Inc. and Click Therapeutics Inc. pondered the signature question of cognitive behavioral therapy when setting the market approach for their jointly developed prescription digital therapeutic for major depressive disorder, Rejoyn.
With a move into Lilly Gateway Labs in Boston’s Seaport District, privately held Tevard Biosciences Inc. is ramping up development of its transfer RNA (tRNA)-based therapies to cure everything from Dravet syndrome and other neurological conditions to cardiology indications and muscular dystrophies.
Neuren Pharmaceuticals Ltd.’s NNZ-2591 met the primary endpoints in a phase II trial in children with Angelman syndrome, with improvements seen in clinically important aspects of the disease, including communication, behavior, cognition and motor abilities, Neuren CEO Jon Pilcher said during an Aug. 9 conference call.
China’s National Medical Products Administration has cleared Luye Pharma Group Ltd.’s new schizophrenia candidate LY-03020 to enter phase I trials in China. Independently developed by Shanghai-based Luye, the new chemical entity is a dual agonist that targets both the trace amine-associated receptor 1 and the 5-HT2C receptor and is intended to treat schizophrenia and Alzheimer’s disease psychosis.
With a move into Lilly Gateway Labs in Boston’s Seaport District, privately held Tevard Biosciences Inc. is ramping up development of its transfer RNA (tRNA)-based therapies to cure everything from Dravet syndrome and other neurological conditions to cardiology indications and muscular dystrophies.
Infection or cure? Scientists from Tel Aviv University and the University of Glasgow genetically modified the Toxoplasma gondii to bring a protein inside neurons. The novelty of using a protozoan that can travel from the gut to parasitize the CNS contrasts with the possibility of causing a disease. The scientists are already working on how to avoid it.
RSS
